Stopping Tyrosine Kinase Inhibitor Treatment in Pediatric and Young Adult Patients with Chronic Myeloid Leukemia in Molecular Remission

Share
Print

Full Title

Stopping Tyrosine Kinase Inhibitors (TKI) to Assess Treatment-Free Remission (TFR) in Pediatric Chronic Myeloid Leukemia - Chronic Phase (CML-CP) (AAML18P1) (CIRB)

Purpose

Patients with chronic myeloid leukemia (CML) at very low levels have what is called “molecular remission.” These patients take medications called tyrosine kinase inhibitors (TKIs), such as imatinib, dasatinib, and nilotinib, for the rest of their lives. In this study, researchers want to see if patients who have been in molecular remission for at least two years can stopped taking TKIs and still maintain their remission. Patients will continue to be monitored periodically. If they lose their remission, they will go back on TKI therapy, which may again achieve remission.

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • This study is for patients diagnosed with chronic phase CML before age 18. Patients must be under age 25 to enter the study.
  • Patients must have received their current TKI for at least three consecutive years and must have been in molecular remission for at least two years.

For more information and to inquire about eligibility for this study, please contact Dr. Christopher Forlenza at 212-639-5226.

Protocol

19-457

Phase

I

Co-Investigators